Highlights and Quick Summary
- Change in payables and accrued liability for the quarter ending June 30, 2022 was $4.99 Million (a -185.94% decrease compared to previous quarter)
- Year-over-year quarterly Change in payables and accrued liability decreased by -10.23%
- Annual Change in payables and accrued liability for 2021 was $9.01 Million (a 825.05% increase from previous year)
- Annual Change in payables and accrued liability for 2020 was $974 Thousand (a 21.45% increase from previous year)
- Annual Change in payables and accrued liability for 2019 was $802 Thousand (a -40.01% decrease from previous year)
- Twelve month Change in payables and accrued liability ending June 30, 2022 was $8.78 Million (a 777.8% increase compared to previous quarter)
- Twelve month trailing Change in payables and accrued liability increased by 47.55% year-over-year
Trailing Change in payables and accrued liability for the last four month:
| 30 Jun '22 | 31 Mar '22 | 31 Dec '21 | 30 Sep '21 |
|---|---|---|---|
| $8.78 Million | $1 Million | $9.01 Million | $5.95 Million |
Visit stockrow.com/PHAS
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Change in payables and accrued liability of PhaseBio Pharmaceuticals
Most recent Change in payables and accrued liabilityof PHAS including historical data for past 10 years.Interactive Chart of Change in payables and accrued liability of PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals Change in payables and accrued liability for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | $4.99 | $-5.81 | – | – | – |
| 2021 | $4.03 | $5.56 | $-2.78 | $2.2 | $9.01 |
| 2020 | $0.97 | $0.52 | $1.13 | $-0.71 | $0.97 |
| 2019 | $0.23 | $0.91 | $0.07 | $-1.53 | $0.8 |
| 2018 | $0.74 | $1.03 | $0.41 | $-0.26 | $1.34 |
| 2017 | – | – | – | $0.2 | $-0.21 |
| 2016 | – | – | – | – | $-0.34 |
Business Profile of PhaseBio Pharmaceuticals
Sector: Healthcare
Industry: Biotechnology